1:02 PM
 | 
Mar 02, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

EC approves Roche’s Hemlibra for hemophilia A

Roche (SIX:ROG; OTCQX:RHHBY) said the European Commission approved once-weekly subcutaneous Hemlibra emicizumab for routine prophylaxis of bleeding episodes in hemophilia A patients with Factor VIII inhibitors.

The pharma said it will work with EU member states...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >